{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:29:04Z","timestamp":1778707744340,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007710","name":"University of Connecticut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bbr.2015.11.008","type":"journal-article","created":{"date-parts":[[2015,11,15]],"date-time":"2015-11-15T09:30:53Z","timestamp":1447579853000},"page":"188-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"PB","title":["The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine"],"prefix":"10.1016","volume":"298","author":[{"given":"Samantha J.","family":"Podurgiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha E.","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Dortche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merce","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Salamone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbr.2015.11.008_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1460-9568.2006.04953.x","article-title":"Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission","volume":"24","author":"Andersson","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2015.11.008_bib0010","first-page":"30","article-title":"Role of selegiline as initial monotherapy in early Parkinson's disease?","volume":"42","author":"Bhatia","year":"1994","journal-title":"J. Assoc. Physicians Ind."},{"issue":"4","key":"10.1016\/j.bbr.2015.11.008_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0091-3057(93)90203-6","article-title":"Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine","volume":"46","author":"Baskin","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2015.11.008_bib0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pbb.2011.05.026","article-title":"Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease","volume":"99","author":"Collins","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.bbr.2015.11.008_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/WNF.0b013e318255838b","article-title":"Selegiline: a reappraisal of its role in Parkinson disease","volume":"35","author":"Fabbrini","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2015.11.008_bib0030","first-page":"62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study","volume":"9","author":"Frank","year":"2009","journal-title":"Neurol"},{"issue":"4","key":"10.1016\/j.bbr.2015.11.008_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","article-title":"Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinectic movement disorders","volume":"8","author":"Guay","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.bbr.2015.11.008_bib0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pbb.2004.12.006","article-title":"Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats","volume":"80","author":"Ishiwari","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2015.11.008_bib0045","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1523\/JNEUROSCI.11-12-03822.1991","article-title":"Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms","volume":"11","author":"Jicha","year":"1991","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2015.11.008_bib0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2015.11.008_bib0055","series-title":"Design and Analysis: A Researcher\u2019s Handbook","author":"Keppel","year":"1991"},{"issue":"4","key":"10.1016\/j.bbr.2015.11.008_bib0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10517-015-2990-x","article-title":"Activity of monoamine oxidase in the nigrostriatal system at presymptomatic and early symptomatic stages of parkinsonism in mice","volume":"159","author":"Khakimova","year":"2015","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bbr.2015.11.008_bib0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo","year":"2004","journal-title":"Pharmacol. Res."},{"issue":"21","key":"10.1016\/j.bbr.2015.11.008_bib0070","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.bmc.2013.08.019","article-title":"Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B) ?","volume":"21","author":"Nag","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbr.2015.11.008_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s007020170089","article-title":"Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study","volume":"108","author":"Negrotti","year":"2001","journal-title":"J. Neural Trans."},{"key":"10.1016\/j.bbr.2015.11.008_bib0080","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","article-title":"An expert opinion on safinamide in Parkinson's disease","volume":"7","author":"Onofrj","year":"2008","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"10.1016\/j.bbr.2015.11.008_bib0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-2999(84)90562-4","article-title":"Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants","volume":"102","author":"Pettibone","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2015.11.008_bib0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neuroscience.2013.07.008","article-title":"The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor","volume":"250","author":"Podurgiel","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2015.11.008_bib0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pbb.2013.01.015","article-title":"Tremorolytic effects of safinamide in animal models of drug-induced Parkinsonian tremor","volume":"105","author":"Podurgiel","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.bbr.2015.11.008_bib0100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/npp.2015.69","article-title":"Fluoxetine administration exacerbates oral tremor and striatal dopamine depletion in a rodent pharmacological model of parkinsonism","volume":"40","author":"Podurgiel","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2015.11.008_bib0105","doi-asserted-by":"crossref","first-page":"e99320","DOI":"10.1371\/journal.pone.0099320","article-title":"The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio\/chow feeding choice task: reversal with antidepressant drugs","volume":"9","author":"Randall","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbr.2015.11.008_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu017","article-title":"Bupropion increases selection of high effort activity in rats tested on a progressive ratio\/chow feeding choice procedure: implications for treatment of effort related motivational symptoms","volume":"18","author":"Randall","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2015.11.008_bib0115","first-page":"225","article-title":"MAO-inhibitors in Parkinson\u2019s disease","volume":"120","author":"Riederer","year":"2011","journal-title":"J. Neural Trans."},{"issue":"4","key":"10.1016\/j.bbr.2015.11.008_bib0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF02247136","article-title":"Lateral striatal mechanisms involved in oral motor activities in the rat","volume":"102","author":"Salamone","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.bbr.2015.11.008_bib0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","article-title":"Tremulous jaw movements in rats: A model of parkinsonian tremor","volume":"56","author":"Salamone","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbr.2015.11.008_bib0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuroscience.2011.07.078","article-title":"Slow phasic changes in nucleus accumbens dopamine release during fixed ratio acquisition: a microdialysis study","volume":"196","author":"Segovia","year":"2011","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.bbr.2015.11.008_bib0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects?","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2015.11.008_bib0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1600-0404.1989.tb01794.x","article-title":"Selegiline and levodopa in early or moderately advanced Parkinson\u2019s disease: a double- blind controlled short- and long-term study","volume":"126","author":"Sivertsen","year":"1989","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.bbr.2015.11.008_bib0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2004.05.027","article-title":"Blockade of adenosine A2A receptors antagonizes Parkinsonian tremor in the rat tacrine model by an action on specific striatal regions","volume":"189","author":"Simola","year":"2004","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2015.11.008_bib0150","first-page":"247","article-title":"Metabolic transformation of deprenyl enantiomers in rats","volume":"7","author":"Sz\u00f6k\u00f6","year":"1999","journal-title":"Neurobiology"},{"issue":"6","key":"10.1016\/j.bbr.2015.11.008_bib0155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/jcbfm.2013.19","article-title":"Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies","volume":"33","author":"Tong","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432815302795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432815302795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T21:25:44Z","timestamp":1767734744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432815302795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":31,"alternative-id":["S0166432815302795"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2015.11.008","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2015.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}